- Home
- MKTX vs ROIV Comparison
MKTX vs ROIV Comparison
Compare MKTX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MKTX
- ROIV
- Stock Information
- Founded
- MKTX 2000
- ROIV 2014
- Country
- MKTX United States
- ROIV United Kingdom
- Employees
- MKTX N/A
- ROIV N/A
- Industry
- MKTX Investment Bankers/Brokers/Service
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- MKTX Finance
- ROIV Health Care
- Exchange
- MKTX Nasdaq
- ROIV Nasdaq
- Market Cap
- MKTX 8.1B
- ROIV 8.4B
- IPO Year
- MKTX 2004
- ROIV N/A
- Fundamental
- Price
- MKTX $215.57
- ROIV $10.79
- Analyst Decision
- MKTX Buy
- ROIV Buy
- Analyst Count
- MKTX 9
- ROIV 4
- Target Price
- MKTX $241.78
- ROIV $17.50
- AVG Volume (30 Days)
- MKTX 538.0K
- ROIV 5.9M
- Earning Date
- MKTX 05-07-2025
- ROIV 05-29-2025
- Dividend Yield
- MKTX 1.41%
- ROIV N/A
- EPS Growth
- MKTX N/A
- ROIV N/A
- EPS
- MKTX 5.76
- ROIV N/A
- Revenue
- MKTX $815,355,000.00
- ROIV $122,585,000.00
- Revenue This Year
- MKTX $8.13
- ROIV N/A
- Revenue Next Year
- MKTX $9.86
- ROIV N/A
- P/E Ratio
- MKTX $37.31
- ROIV N/A
- Revenue Growth
- MKTX 7.33
- ROIV 140.04
- 52 Week Low
- MKTX $186.84
- ROIV $8.73
- 52 Week High
- MKTX $296.68
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- MKTX 44.61
- ROIV 50.06
- Support Level
- MKTX $209.80
- ROIV $10.58
- Resistance Level
- MKTX $232.84
- ROIV $11.77
- Average True Range (ATR)
- MKTX 6.33
- ROIV 0.34
- MACD
- MKTX -1.80
- ROIV -0.07
- Stochastic Oscillator
- MKTX 21.79
- ROIV 17.65
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.